Results of a clinical trial published today in STEM CELLS are the first to document the safety and feasibility of the early administration of bone marrow cells to treat acute ischemic stroke patients.
DURHAM, N.C., Sept. 17, 2019 /PRNewswire-PRWeb/ --Results of a clinical trial published today in STEM CELLS are the first to document the safety and feasibility of the early administration of bone marrow cells to treat acute ischemic stroke patients. The information provided by the study could aid in developing new cellular therapies for this most common form of stroke caused by a blocked artery which affects over 13 million people each year, according to the World Health Organization.
The study in STEM CELLS is a follow up to the initial report on the first 10 patients in the trial, published in the Annals of Neurology in 2011. The STEM CELLS paper represents the total group of 25 patients.
Sean Savitz, M.D., director of the Institute for Stroke and Cerebrovascular Disease and professor of neurology at McGovern Medical School at UTHealth Houston, was lead investigator on the study. "Having found no clear evidence of harm to the initial 10 patients," he said, "we broadened the inclusion criteria and enrolled additional patients. Our choice of cell type bone marrow mononuclear cells (BM MNCs) dose (10 million cells/kg), timing; route of administration; and the autologous approach was based on, and is in line with, growing evidence from animal stroke models and clinical evidence for possible treatment effects in our traumatic brain injury studies and other diseases."
BM MNCs are attractive in regenerative medicine studies because they can be rapidly isolated; are enriched with hematopoietic, mesenchymal and endothelial progenitor cells; and permit autologous applications. Preclinical studies consistently indicate that MNCs improve outcome when administered within 72 hours of stroke onset and at least one clinical trial has shown they are not effective beyond seven days, the researchers said.
The regenerative potential of BM-derived MNCs is attributed to various mechanisms that impact stroke recovery. The cells migrate to the site of injury, release cytokines and other trophic factors, decrease proinflammatory and upregulate anti-inflammatory pathways, among other things. They also are easily amenable to autologous infusion, eliminating the need for immunosuppressive drugs.
"In contrast to the generation of autologous mesenchymal stem cells, another promising cell therapy," added Dr. Savitz, "MNCs do not require passage in culture, which allows for testing in the early post-stroke time window."
Each patient in the Savitz team's study received an intravenous dose of their own BM MNCs within 72 hours after onset of their stroke. They were then followed for one year after treatment and the results compared to a control group of 185 acute ischemic stroke patients who received conventional treatment only. No definite severe adverse events related to the procedures were seen in any of the 25 patients, the research showed.
"In the light of our findings," said Dr. Savitz, "we believe that MNCs pose no additional harm in ischemic stroke patients when given during the acute phase, doses up to 10 million cells/kg are tolerated and it is feasible to perform a BM harvest and re-infusion of MNCs for a wide range of stroke patients. Well-designed random clinical trials are needed to further assess safety and efficacy of this novel approach to enhance stroke recovery."
"New options to treat Ischemic stroke are desperately needed," said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. "This important clinical trial provides solid safety and feasibility data on which later trials can be built, using the patient's own bone marrow stem/progenitor cells to potentially enhance recovery after ischemic stroke."
The full article, "Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3080.
About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.
About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS (http://www.StemCells.com) is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.
- Growing Value of Stem Cells in Medicine to Create a US$2,4 Billion Opportunity for Induced Pluripotent Stem Cell ((iPSC) - GlobeNewswire - November 27th, 2020
- Induced Pluripotent Stem Cells Market New Research Study Report with Size, Share, Trends, Emerging Applications, Opportunities and Worldwide Analysis... - November 27th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market Applications, Types and Future Ou - News by aeresearch - November 27th, 2020
- Research Paper Showing ProtoKinetix AAGP Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision - Business Wire - November 27th, 2020
- Induced Pluripotent Stem Cells Market 2020: Enhanced Growth, Recent Trends and Major Companies are Fujifilm Holding Corporation, Astellas Pharma, Fate... - November 27th, 2020
- The Stem Cell-Derived Cells market to Scale new heights in the next decade - Khabar South Asia - November 27th, 2020
- Astronaut Soichi Noguchi still adapting to life on ISS - The Japan Times - November 27th, 2020
- Potential new therapies for Alzheimer's disease are revealed through network modeling of its complex molecular interactions - Science Codex - November 27th, 2020
- Global Induced Pluripotent Market To Perceive Biggest Trend And Opportunity With Key Players CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher... - November 22nd, 2020
- Global Stem Cell Banking Market 2020: Overview, Trends, Opportunities, Impact of Drivers, Key Vendors, Types, Applications, Forecast by Focusing... - November 22nd, 2020
- Thanyapura, StemCells21 to offer premium stem cell treatments in Thailand - BSA bureau - November 20th, 2020
- Neurons stripped of their identity are hallmark of Alzheimer's disease, study finds - National Science Foundation - November 20th, 2020
- Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Newswise - November 20th, 2020
- Stem Cells Market Value Expected To Reach $17.79 Billion By 2027 - Eurowire - November 20th, 2020
- How regenerative medicine could be used to contain COVID-19, others - Guardian - November 20th, 2020
- The Induced Pluripotent Stem Cells Market To Witness Fierce Competition Amongst The Key Players - KYT24 - November 18th, 2020
- at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Fred Hutch News Service - November 18th, 2020
- Neurons stripped of their identity are hallmark of Alzheimers disease, study finds - Newswise - November 18th, 2020
- Genetic influences on viral-induced cytokine responses in the lung - DocWire News - November 18th, 2020
- Japanese and U.S. astronauts arrive at ISS in SpaceX ship - The Japan Times - November 18th, 2020
- AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - BioSpace - November 18th, 2020
- Coadministration of endothelial and smooth muscle cells derived from human induced pluripotent stem cells as a therapy for critical limb ischemia -... - November 12th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market Size, Drivers, Potential Growth Opportunities, Competitive Landscape, Trends And Forecast To 2027 -... - November 12th, 2020
- Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells - BioSpace - November 12th, 2020
- Global Induced Pluripotent Stem Cells Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2026 -... - November 12th, 2020
- Stem Cell Manufacturing Market Share & Size, Future Growth, Trends Evaluation, Demands, Regional Analysis and Forecast to 2027| Merck Group,... - November 12th, 2020
- Induced Pluripotent Stem Cells Market Comprehensive Insights, Growth, Forecast and Covid-19 Impact by 2026 | Medipost Co. Ltd., Ocata Therapeutics... - November 12th, 2020
- Induced Pluripotent Stem Cells Industry Market 2020 Global Trends, Key Players, Share, Growth, Analysis, Opportunities and Forecast To 2026 -... - October 31st, 2020
- The Stem Cell-Derived Cells market to be in conjunction to growth from 2020 to 2030 - PRnews Leader - October 31st, 2020
- In Vitro Toxicology Testing Market: Facts, Figures and Analytical Insights, 2018 to 2024 - Aerospace Journal - October 31st, 2020
- Bayer Acquires AskBio to Expand Gene Therapy Platform - PharmaLive - October 31st, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 with COVID-19 After Effects Growth Drivers, Top Key Players, Industry Segments and Forecast... - October 29th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By... - October 29th, 2020
- Global Induced Pluripotent Stem Cells Market Analysis by Size: 2025, Impact of Covid-19 on Industry Chain, Market Growth, Drivers | Business Overview... - October 29th, 2020
- The Induced Pluripotent Stem Cells Market To Witness A Major Breakthrough In The Form Of A Double-Digit CAGR Of 7% - KYT24 - October 29th, 2020
- Emulate Signs Collaborative Agreement with the FDA to Apply Lung-Chip to Evaluate Safety of COVID-19 Vaccines and Protective Immunity Against... - October 29th, 2020
- QurAlis Announces Appointment of New Chief Medical Officer and Formation of Clinical Advisory Board - BioSpace - October 29th, 2020
- AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute... - October 29th, 2020
- Bayer Acquires AskBio for Up to $4 Billion to Expand Gene Therapy Platform - BioSpace - October 29th, 2020
- How Will the Virus Epidemic Cause Induced Pluripotent Stem Cells (iPSCs) Market 2020 - The Think Curiouser - October 24th, 2020
- Trends in the Ready To Use Induced Pluripotent Stem Cells Market 2020-2020 - Eurowire - October 24th, 2020
- Stem Cell-Derived Cells Market to Expand at a Healthy CAGR of XX% Between and 2019 2029 - Eurowire - October 24th, 2020
- The Induced Pluripotent Stem Cells Market To Mark Robustness In The Form Of A Robust CAGR - KYT24 - October 23rd, 2020
- COVID-19 can affect the heart - Science Magazine - October 23rd, 2020
- Kobe Hospital Trials Transplant to Reverse Blindness A First in the World - JAPAN Forward - October 23rd, 2020
- Rethinking the Link between Cannabinoids and Learning - Lab Manager Magazine - October 23rd, 2020
- Cold sore virus can spread to unborn babies harming their brains, docs warn - The Sun - October 23rd, 2020
- Microscopy Beyond the Resolution Limit - Lab Manager Magazine - October 21st, 2020
- AMSBIO Launches New Human iPSC-Derived Cells and iPSC Differentiation Reagent Kits - Technology Networks - October 20th, 2020
- Induced Pluripotent Stem Cells Market To Grow At 7% YOY In Forecast Years 2026 - The Think Curiouser - October 20th, 2020
- Groundbreaking eye surgery in Kobe offers hope to sight impaired : The Asahi Shimbun - Asahi Shimbun - October 20th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Industry 2020 Includes The Major Application Segments And Size In The Global Market To 2026 - PRnews Leader - October 16th, 2020
- Induced Pluripotent Stem Cells Market 2020 Is Slated to Grow Rapidly in the Forthcoming Years with Key Players Addgene, Axol Bioscience, Cell... - October 16th, 2020
- Disruptive Technologies and Mature Regulatory Environment Vital for Cell Therapy Maturation - BioSpace - October 16th, 2020
- Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome... - October 16th, 2020
- Brain organoids reveal neuronal flaws in syndrome tied to autism - Spectrum - October 16th, 2020
- Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry - BioSpace - October 16th, 2020
- Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting - GlobeNewswire - October 16th, 2020
- Global Stem Cell Therapy Market 2020: Trends, and Opportunity Analysis, Top Manufacturers And Forecast to 2027 - PRnews Leader - October 16th, 2020
- Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients |... - October 8th, 2020
- Dolly the Sheep: '90s Media Sensation - Mental Floss - October 8th, 2020
- Regeneron, Pfizer and BioNTech Accused of Infringing Allele Patent in Connection with COVID-19 Technologies - IPWatchdog.com - October 8th, 2020
- Yufan inks deal with Abound to develop antibodies directing CAR T cells against cancer targets - BioWorld Online - October 7th, 2020
- Allele Biotechnology and Pharmaceuticals Files Two Lawsuits for Patent Infringement for the Unauthorized Use of mNeonGreen in Development and Testing... - October 7th, 2020
- Huge Investment in Induced Pluripotent Stem Cells Market Expected to Witness the Highest Growth 2026 | Fujifilm Holding Corporation (CDI) Ncardia,... - October 3rd, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 - 2029 - Stock Market Funda - October 3rd, 2020
- Kyoto University project aims to supply iPS cells widely at low cost - The Japan Times - September 29th, 2020
- ONLINE: The Future of Medicine - Isthmus - September 29th, 2020
- funded study sheds light on abnormal neural function in rare genetic disorder - National Institutes of Health - September 29th, 2020
- Stem Cell Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle - September 29th, 2020
- The new pharma collaborations driving transformative research in oncology - - pharmaphorum - September 29th, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Manufacturer Analysis, Technology Advancements, Industry Scope and Forecast to 2027||Fate... - September 21st, 2020
- Induced Pluripotent Stem Cells Market to Witness Huge Growth by 2025| Bone Therapeutics SA, System Biosciences, Axiogenesis, Regeneus Ltd.,... - September 14th, 2020
- Global Stem Cells Market Report, History And Forecast 2020-2027, Breakdown Data By Manufacturers, Key Regions, Types And Application - Bulletin Line - September 11th, 2020
- New DNA Recovery Technique Reveals Richer Picture of the Past - Lab Manager Magazine - September 11th, 2020
- Study Identifies New Set of Genes That May Explain Why People with Down Syndrome Have a Higher Risk of Leukemia - DocWire News - September 10th, 2020
- Patenting Stem Cell Inventions in India- What to Expect? - Lexology - September 10th, 2020
- Scientists May Have Discovered a Way to to Slow Aging by Direct Reprogramming of Human Cells - SciTechDaily - September 10th, 2020
- Induced Pluripotent Stem Cells Market Global Growth Analysis and Forecast to 2024 | Top Players (BlueRock Therapeutics, Corning Life Sciences, EMD... - September 10th, 2020
- Study: The Speed Neurons Fire Impacts Their Ability to Synchronize - Lab Manager Magazine - September 10th, 2020